Specific analysis of S100A4 and PTGS2 scores for patients identified as positive in the multi-target stool mRNA test could contribute to discriminating between patients carrying AA vs. those with CRC considering that, for instance, a patient with a score >4.5 for S100A4 and PTGS2 displays a 17% probability of having an AA vs. 73% odds of having a CRC. Here, PTGS2 is linked to colorectal carcinoma.